Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.
An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.
Stereotactic body radiotherapy has a favorable long-term disease control and safety profile in the setting of low- or intermediate-risk prostate cancer, say US researchers who analyzed individual patient data from over 2000 prospectively treated men.
US patients with low-risk localized prostate cancer are increasingly being managed with active surveillance or watchful waiting, finds a database analysis.
Supplementing androgen deprivation therapy with docetaxel does not appear to improve the outcomes of men with high-risk nonmetastatic prostate cancer and rising prostate-specific antigen levels after treatment, indicate phase III trial findings.
Modest differences in the time from diagnosis to radical prostatectomy do not appear to affect the outcomes of men with high- or very-high-risk prostate cancer, say the authors of a chart review.
A population-based study has not replicated the previously reported association between Alzheimer’s dementia and androgen deprivation therapy, but suggests that the risk for non-Alzheimer’s dementia may be elevated with use of gonadotropin-releasing hormone agonists and orchiectomy.
Germline mutations in the BRCA2 gene, but not other DNA damage repair genes, are associated with poorer outcomes among patients with metastatic castration-resistant prostate cancer, study findings indicate.
The presence of the microsatellite instability-high/mismatch repair-deficient phenotype could help select advanced prostate cancer patients who are likely to derive durable clinical benefit from treatment with checkpoint inhibitors, say researchers.
Patients treated with 18 months of androgen suppression plus radiotherapy have a significantly lower rate of prostate cancer-specific death at 10 years than those who receive 6 months of androgen suppression and radiotherapy, researchers report.
Men with localised prostate cancer derive long-term survival benefits from radical prostatectomy relative to watchful waiting, indicate the 29-year follow-up results of the SPCG-4 trial.
Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.
Treatment with radical prostatectomy plus adjuvant external beam radiotherapy and androgen deprivation therapy can offer equivalent survival outcomes to a nonsurgical approach in patients with high-risk prostate cancer, research shows.
Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.
In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.
The latest results from the STAMPEDE trial do not show an additional overall survival benefit with radiotherapy for men undergoing androgen deprivation therapy with or without docetaxel for newly diagnosed metastatic prostate cancer.
Men with metastatic castration-resistant prostate cancer who are beginning treatment with abiraterone acetate plus prednisone may not need luteinizing hormone-releasing hormone therapy, suggest exploratory findings presented at the ESMO 2018 Congress in Munich, Germany.
An updated analysis of the NRG/RTOG 9413 trial shows that the benefits of whole pelvic radiotherapy plus neoadjuvant hormonal therapy persist in the long term in patients with intermediate- or high-risk localised prostate cancer.
Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.
The addition of apalutamide to androgen deprivation therapy has no detrimental effect on health-related quality of life in men with nonmetastatic castration-resistant prostate cancer, an analysis of data from the SPARTAN trial shows.